|  |  |  |
| --- | --- | --- |
| Primer Name | Sequences 5’ to 3’ | Length |
| TP53 EXON 5 FP | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACTCTGTCTCCTTCCTCTTCCT | 55 |
| TP53 EXON 5 RP | GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACCAGCCCTGTCGTCTCTTC | 54 |
| TP53 EXON 6 FP | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGGGTCCCCAGGCCTCT | 50 |
| TP53 EXON 6 RP | GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGCCCCCCTACTGCTCAC | 52 |
| TP53 EXON 7 FP | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGCCTCATCTTGGGCCTG | 52 |
| TP53 EXON 7 RP | GTCTCGTGGGCTCGGAGATGTGTATAGAGACAGGGTCAGAGGCAAGCAGAGG |  |
| TP53 EXON 8 FP | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGGAGTAGATGGAGCCTGGT | 53 |
| TP53 EXON 8 RP | GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCGCTTCTTGTCCTGCTTGC | 54 |
| TP53 EXON 9 FP | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGAGGAGACCAAGGGTGCA | 52 |
| TP53 EXON 9 RP | GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGCAAATGCCCCAATTGCAGG | 55 |
| PIK3CA FP | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTGAGCAAGAGGCTTTGGAGTA | 55 |
| PIK3CA RP | GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTGCAATTCCTATGCAATCGGTCT | 58 |

Supplementary Table 1- Primers for TP53 and PIK3CA, designed based on the guideline provided in 16S metagenomic sequencing library preparation (15044223 B) manual for NGS

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table 2-Clinical characteristics of patients: Clinico-pathological characteristics of (n=132) patients with primary tumors   |  |  | | --- | --- | |  | **n = 132 patients (%)** | | **Age** |  | | Mean (Yrs) | 56 | | Median (Yrs) | 56 | |  |  | | **Tumor Size** |  | | Mean (cm) | 3.6 | | Median (cm) | 3 | |  |  | | **Stage** |  | | I | 21 (18) | | II | 59(50) | | III | 37 (32) | |  |  | | **Grade** |  | | 0&1 | 24 (19) | | 2 | 71 (55) | | 3 | 27 (21) | | NA | 6 (5) | |  |  | | **Menopausal status** |  | | Pre | 33 (26) | | Post | 96 (74) | |  |  | | **Lymph node status** |  | | Positive | 53 (42) | | Negative | 72 (58) | |  |  | | **Estrogen Receptor** |  | | Positive | 77 (61) | | Negative | 50 (39) | |  |  | |  |  | | **HER2** |  | | Positive | 19 (15) | | Negative | 103 (81) | | Equivocal | 5 (4) | |  |